West Pharmaceutical Services (WST) Non Operating Income (2011 - 2026)

West Pharmaceutical Services (WST) has reported Non Operating Income for 16 consecutive years, with -$12.8 million the latest figure, recorded in Q2 2026.

• Quarterly Non Operating Income fell 146.15% year-over-year to -$12.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$42.2 million (down 4.46% YoY) and the FY2025 annual result came in at -$51.2 million, down 143.81% from the prior year.
• Non Operating Income declined to -$12.8 million in Q2 2026 per WST's latest filing, from -$4.0 million in the prior quarter.
• Over the last five years, Non Operating Income for WST reached as high as $26.3 million in Q4 2022 and fell as low as -$50.0 million in Q3 2022.
• A 5-year average of -$6.8 million and a median of -$4.8 million in 2024 frame the typical range for Non Operating Income.
• The largest YoY upside for Non Operating Income was 636.73% in 2022 against a maximum downside of 2677.78% in 2022.
• Year by year, Non Operating Income stood at $26.3 million in 2022, then tumbled by 133.84% to -$8.9 million in 2023, then slipped by 14.61% to -$10.2 million in 2024, then slumped by 81.37% to -$18.5 million in 2025, then soared by 30.81% to -$12.8 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$12.8 million, -$4.0 million, and -$18.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.